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ess: l.donnelly@imperiaSummary Asthma and chronic obstructive pulmonary disease (COPD) are different
conditions with contrasting airway inflammation and parenchymal disease patterns.
A number of matrix metalloproteases (MMPs) are implicated in the pathophysiology
of COPD and asthma. Different profiles of airway MMPs may, therefore, be expected
in asthma and COPD. The present study compared MMP profiles in the airways of non-
smokers, non-symptomatic cigarette smokers, and patients with COPD or asthma
(n ¼ 15 subjects per group). Induced sputum was assessed for MMP-1, -2, -3, -8 and -
9, and tissue inhibitor of metalloproteases (TIMP)-1 by ELISA. Gelatinase activity was
determined by zymography. Sputum from COPD patients contained increased levels
of MMP-1, -8 and -9 compared with the other groups (2–7-fold, depending upon
group). MMP-9 activity was elevated in COPD sputum by 3–12-fold above the other
groups. Sputum from COPD patients had 3-fold higher levels of TIMP-1 than samples
from asthmatics or controls, but was not different to smokers. FEV1 correlated
negatively with MMP-1, -8, -9, MMP-9 activity and TIMP-1, whereas percent
neutrophils in sputum correlated positively with MMP-1, -8, -9, TIMP-1 and MMP-9
activity. The MMP profile in COPD differs to that in asthma and cigarette smokers.
This may contribute to, or be a marker of, different pathophysiologies of asthma and
COPD.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
20 7352 8121x3061; fax:
l.ac.uk (L.E. Donnelly).Introduction
Airway inflammation is a feature common to
asthma and chronic obstructive pulmonary disease
(COPD).1,2 However, the ‘profile’ of the inflamma-
tion differs between the two conditions.3 COPD is aed.
ARTICLE IN PRESS
S.V. Culpitt et al.704debilitating respiratory disease characterised by
progressive and largely irreversible airflow limita-
tion.4 Cigarette smoking is the major risk factor for
development of COPD, and smoking cessation is
currently the only intervention that slows disease
progression.5,6 COPD comprises three disease com-
ponents, namely chronic bronchitis (mucous hyper-
secretion), chronic bronchiolitis (also known as
small airways disease) and emphysema (alveolar
destruction).7 The contribution of each component
to disease status and clinical presentation varies
from one patient to another. Endogenous protease
activity is implicated in the pathophysiology of
each of these three disease components.8,9 In
contrast to COPD, asthma is defined as a clinical
entity characterised by variable airflow obstruction
and increased airway responsiveness that is rever-
sible, either spontaneously or with treatment.10
Proteases are also implicated in part in the
pathophysiology of asthma.11,12 In particular, ma-
trix metalloproteinases (MMPs), a large family of
proteolytic enzymes that degrade the components
of extracellular matrix,13,14 are implicated in the
pulmonary remodelling processes that underlie
both asthma and COPD.15,16
A number of studies have examined the expres-
sion of individual MMPs in either asthma or COPD
and compared it with healthy control subjects. For
example, there is increased expression of the
collagenases MMP-1 and -8 in asthmatic airways
compared with non-asthmatic controls 17,18 and in
the airways of patients with emphysema compared
with healthy subjects.19,20 Similarly, the gelati-
nases MMP-2 and -9 are upregulated in asthmatic
airways compared with healthy controls 21,22 and in
the airways of patients with emphysema compared
with healthy subjects.23 In contrast, MMP-3 (stro-
melysin-1) is not up-regulated in asthma compared
with healthy volunteers,24 with no reports of its
expression in the lung in COPD. MMP activity isTable 1 Clinical characteristics of control subjects, asth
Parameter Controls Asthmatics
Age (yr) 30.571.4 34.671.6
Sex (F:M) 9:6 9:6
FEV1% predicted 104.971.7 93.571.1**
FVC % predicted 104.271.7 102.571.1
FEV1:FVC ratio 0.7870.01 0.7470.01
Pack years 0 0
*Po0.05, **Po0.01, ***Po0.001 compared with equivalent value
#Po0.05, ###Po0.001 compared with equivalent value for asthm
+Po0.05, ++Po0.01, +++Po0.001 compared with equivalent value
FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capac
*Values are mean7SEM for 15 subjects in each group.regulated by endogenous inhibitors termed tissue
inhibitors of metalloproteinase (TIMPs), which are
also elevated in asthma 25 and COPD.26 However, to
the knowledge of the authors, there has been no
direct comparison of airway MMP and TIMP expres-
sion between patients with asthma and patients
with COPD.
The aim of the present study was to compare and
contrast the concentrations of MMP-1, -2, -3, -8 and
9, together with TIMP-1, in induced sputum from
patients with asthma and patients with COPD. Non-
smoking subjects and non-symptomatic cigarette
smokers were included as relevant controls. In
addition, the enzymatic activity of MMP-9 was
assessed using gelatin zymography. Moreover, glu-
cocorticosteroids down-regulate MMP expression,
and upregulate TIMP expression, in asthma.27
Consequently, we recruited mild asthmatics who
were not currently taking glucocorticosteroids,
which might confuse interpretation of the data. In
addition, they were matched for pharmacotherapy
with the COPD patients (bronchodilator therapy
alone).Methods
Subjects
Four groups of subjects were recruited: 15 patients
with COPD (cigarette smokers), diagnosed accord-
ing to current standard criteria,4 15 patients with
asthma (non-smokers), diagnosed according to
current standard criteria, including a personal
history of asthma,10 15 current smokers without
airways obstruction (FEV1480% predicted) and 15
non-smoking control subjects without lung disease
(Table 1). Smokers and COPD patients had a
smoking history of 420 pack years. Six of thematic patients, cigarette smokers and COPD patients*.
Non-COPD smokers COPD smokers
47.672.6*** # 60.772.6*** ### ++
10:5 3:12
100.971.2 45.273.1*** # +++
100.070.9 93.171.6*** ### +
0.7470.01 0.4370.04*** # ++
28.872.5 41.971.0++
for controls.
atics.
for smokers.
ity.
ARTICLE IN PRESS
Sputum MMPs in COPD and asthma 705COPD patients could be classified as stage II, eight
patients as stage III and one patient as stage IV.4
None of the current smokers could be classified as
stage 0 COPD. The asthmatic patients had bronchial
hyperreactivity as evidenced by a PC20 methacho-
line of o4mg/ml. Otherwise, the asthmatic pa-
tients were considered to be mild and clinically
stable, with no change in treatment for at least 8
weeks prior to study and no more than four short
courses of oral corticosteroids (o2 weeks) during
the preceding year. Asthmatic subjects maintained
their current therapy (i.e. b2-agonists alone, with
no inhaled or oral glucocorticosteroids for at least 8
weeks prior to the study), as did the COPD patients
(i.e. b2-agonists and/or anticholinergics only).
Neither the asthmatic nor the COPD patients had
suffered an exacerbation for at least 8 weeks prior
to the study. Smokers were unmedicated. The study
was approved by the Ethics Committee of the Royal
Brompton and Harefield NHS Trust, and subjects
gave informed written consent.
Sputum induction
Sputum was induced via inhalation of hypertonic
saline as previously described, and was processed
for differential counts of inflammatory cells.28
MMP measurements
The concentrations of total MMP and TIMP-1 in
sputum supernatant were determined using paired
antibody quantitative ELISAs and appropriate
blanks (Amersham Life Sciences, Little Chalfont,
UK). The assay detected both active and latent
forms of MMPs. The presence of dithiothreitol (DTT)
(0.05% w/v) in the sputum samples reduced the
sensitivity of the assays. However, this was con-
trolled for by inclusion of DTT in the standards for
each ELISA. The lower limit of detection of the
assays was 1.8 ng/ml for MMP-1, 0.4 ng/ml for MMP-
2, 2.4 ng/ml for MMP-3, 32 pg/ml for MMP-8,
0.6 ng/ml for MMP-9 and 1.3 ng/ml for TIMP-1.
Zymography
Sputum supernatant was incubated with b-galacto-
sidase (30 i.u. per 100 ml) for 2 h with shaking at
37 1C to partially digest mucopolysaccharides in
order to improve resolution of the sputum samples
on the zymographic gel. Sputum protein content
was measured using the BioRad protein assay
reagent according to the manufacturer’s instruc-
tions (BioRad Ltd., Hemel Hempstead, UK). Two
micrograms of sputum protein was diluted withTris-Glycine sodium dodecyl sulphate (SDS) sample
running buffer (0.25M Tris-HCl containing glycerol
20% v/v, 4% w/v SDS and 0.05% w/v bromophenol
blue), and zymography performed as described
previously.29 It should be noted that MMP-2 activity
was not detected in any of the samples (see
Results). Consequently, gelatinase activity in these
samples was due to MMP-9. Standards of 0.1 mg
human recombinant active MMP-9 (Oncogene Re-
search Products, Cambridge, MA, USA) were re-
solved on each gel to provide a reference for
gelatinase activity (MMP-2 and MMP-9) in the
samples. Gels were analysed using the Gelworks
(UVP Ltd., Cambridge, UK) software system which
calculated a measurement of gelatinase activity
according to band thickness and density. MMP-9
activity in the samples was expressed as a
percentage of the MMP-9 standard for each gel.
Statistical analysis
Comparisons between subject groups were made
using the Kruskal–Wallis test followed by Dunn’s
multiple comparison test, or a Student’s t-test
where applicable. The significance of the relation-
ship between two variables was assessed using
Spearman’s rank correlation coefficient. The null
hypothesis was rejected at Po0:05:Results
Clinical characteristics of subjects
The current smokers and patients with COPD were
older than both the asthmatic patients and the non-
smoking controls (Table 1). The patients with COPD
were older than the current smokers and had
smoked more cigarettes. None of the current
smokers had an FEV1:FVC ratio of o0.7, indicating
that they were not stage 1 COPD subjects according
to GOLD criteria.4 We cannot anticipate whether or
not these subjects would in later life develop COPD
and, therefore, have specifically not referred to
them herein as ‘healthy’ smokers.
Inflammatory cell counts
There were no significant differences in the total
number of inflammatory cells recovered in sputum
from any of the groups (Table 2). Patients with
COPD had a significantly reduced percentage
macrophage count and an increased percentage
neutrophil count compared with any of the other
groups (Table 2). Eosinophils were not detected in
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Table 2 Induced sputum total cell counts and differential cell counts*.
Parameter Controls Asthmatics Non-COPD smokers COPD smokers
Patient number 15 (9F) 15 (9F) 15 (10F) 15 (3F)
Total Inflammatory cells ( 106/ml) 2.370.5 2.170.4 1.970.3 5.271.5
Macrophages (%) 58.371.5 59.172.6 48.171.7 21.571.9*** ### +
Macrophages ( 106/ml) 1.570.4 1.270.2 0.970.2 0.870.2
Neutrophils (%) 40.871.5 36.971.9 51.571.7## 77.771.9*** ### +
Neutrophils ( 106/ml) 0.970.2 0.870.2 0.970.1 4.371.3* ##
*Po0.05, ***Po0.001 compared with equivalent value for controls.
##Po0.01, ###Po0.001 compared with the equivalent value for asthmatics.+Po0.05, compared with the equivalent value for
smokers.
*Data are mean7SEM for 15 subjects in each group.
S.V. Culpitt et al.706sputum of normal controls, smokers or COPD
patients, whereas patients with asthma had a mean
% eosinophil count of 2.7% (s.e.m. 0.8%).MMP concentrations
MMP-1 was significantly increased in the sputum of
patients with COPD, with increases in median
values of almost 4-fold above controls, 3-fold
above asthmatics and 2-fold above smokers (Fig.
1, panel A). In contrast, there were no significant
differences in concentrations of either MMP-2 or -3
between the four subject groups (Fig. 1, panels B
and C). MMP-8, however, was increased in the
sputum of patients with COPD, with increases in
median values of 4-fold above controls, 5-fold
above asthmatics and 3-fold above smokers (Fig.
1, panel D). Similarly, MMP-9 was increased in the
sputum of patients with COPD, with increases in
median values of 8.5-fold above controls, 6.5-fold
above asthmatics and 4-fold above smokers (Fig. 1,
panel E). In addition, there was an increase of 2-
fold in the sputum of smokers above that of
controls or asthmatics. TIMP-1 was increased in
the sputum of patients with COPD above that in
controls and asthmatics (3-fold increase for both
subject groups), but with no significant change
compared with smokers (Fig. 1, panel F). In
addition, TIMP-1 was elevated in the sputum of
smokers compared with that of controls or asth-
matics (3-fold increase for both).MMP activity
Active MMP-9 (86 kDa band) was significantly
elevated in the sputum of patients with COPD
(Fig. 2, panel A), with increases in median values of
12-fold above controls, 5-fold above asthmatics
and 3-fold above smokers (Fig. 2, panel B). Inaddition, MMP-9 activity was increased in the
sputum of smokers compared with controls by
4.5-fold. There was no increase in activity in the
sputum from the asthmatics (Fig. 2, panel B). MMP-
2 activity was not detected in any of the sputum
samples (data not shown). The high molecular
weight zones of lysis on the zymography gels
corresponded to latent MMP-9. b-galactosidase did
not lyse the gels (data not shown).Relationship between MMP and TIMP-1 with
lung function and sputum inflammatory cells
MMP-8 and -9 concentrations and activity corre-
lated negatively with FEV1 (Table 3; Fig. 3, panels A
and D). Similarly, MMP-1 and TIMP-1 concentra-
tions, but not MMP-2 or MMP-3, also correlated
negatively with FEV1. MMP-8 concentrations and
MMP-9 concentrations and activity correlated posi-
tively with both the percentage (Table 3; Fig. 3,
panels B and E) and number of neutrophils (Table
3). Similarly, MMP-1 and TIMP-1 concentrations, but
not MMP-2 or MMP-3, also correlated positively with
the percentage and number of neutrophils. MMP-8
concentrations and MMP-9 concentrations and
activity correlated negatively with the percentage
of macrophages (Table 3; Fig. 3, panels C and F).
Similarly MMP-1 and TIMP-1 concentrations, but not
MMP-2 or MMP-3, correlated negatively with the
percentage of macrophages. No correlations were
observed with macrophage numbers. There was
also no correlation between MMP-8 levels and FEV1
or neutrophil count, or between MMP-9 activity and
FEV1 or neutrophil count for any of the individual
groups. Similarly, there was no correlation between
MMP-9 activity, % neutrophils or % macrophages and
age for any of the subject groups. There was also no
correlation between age and MMP-8 concentrations
for normal controls and COPD patients. However,
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Figure 1 Concentrations of MMPs and tissue inhibitor of MMP (TIMP)-1 in induced sputum from control subjects,
asthmatics, cigarette smokers and patients with COPD. Panel A ¼ MMP-1, panel B ¼ MMP-2, panel C ¼ MMP-3, panel
D ¼ MMP-8, panel E ¼ MMP-9 and panel F ¼ TIMP-1. Po0:05; Po0:01; Po0:001:
Sputum MMPs in COPD and asthma 707MMP-8 correlated negatively with age in the
asthmatic group (r ¼ 0:57; Po0:05) and positively
with age in the smokers (r ¼ 0:58; Po0:05).Discussion
In the present study, MMP-1, -8, and -9, were
increased in sputum from patients with COPD
compared with patients with asthma. To our
knowledge, this is the first direct demonstration
of differences in pulmonary MMP expression be-
tween asthma and COPD. The levels of these MMPs
in COPD sputum were also increased compared with
non-smokers and current cigarette smokers without
COPD. This is consistent with observations that
these MMPs are elevated in the lungs of patientswith COPD.20,23,30 The increase in concentration of
MMP-9 in sputum from patients with COPD may be
related to smoking status, since MMP-9 levels were
also elevated in the sputum from smokers, or may
be due to age differences within our groups.
However, it is noteworthy that there was no
significant correlation between, for example,
smoking history (pack years) and MMP-9 activity
(r ¼ 0:33). Similarly, there was an overall lack of
positive correlation between age and the inflam-
matory markers measured herein, except for MMP-8
in the smokers. Herein, there was no change in
MMP-2 or MMP-3 in the sputum of COPD patients.
This differs from the observation of increased MMP-
2 levels in lung tissue from patients with emphy-
sema.31 The reason(s) underlying this discrepancy
may relate to sampling differences. The present
study used induced sputum whereas the cited study
ARTICLE IN PRESS
S.V. Culpitt et al.708examined lung tissue. Alternatively, the discre-
pancy could be related to different study popula-
tions since it is reported that MMP-2 activity is
detected in induced sputum in only 25% of a cohort
of COPD patients.32 In the present study, TIMP-1
was elevated in COPD patients compared with the
other groups. This is consistent with the observa-
tion that sputum TIMP-1 levels were enhanced in
COPD compared with healthy subjects.26 Whilst
elevated levels of TIMP-1 might be expected to
nullify the increased expression of MMP-1 shown
herein, TIMP-1 can bind to and inhibit all MMPs.33
Therefore, the increase in TIMP-1 expression
observed in COPD may not be sufficient to counter-Controls Asthmatics Smokers COPD
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Figure 2 MMP-9 activity in induced sputum from control
subjects, asthmatics, cigarette smokers and patients
with COPD. Panel A shows a representative gelatin
zymogram of MMP-9 activity in individual subjects from
the different groups: C ¼ controls, A ¼ asthmatic pa-
tients, S ¼ smokers and COPD patients. MMP-9 is in-
creased in the smokers and patients with COPD. Panel
B ¼ group data. Po0:05; Po0:001:
Table 3 Relationship between MMPs and TIMP-1 with lu
FEV1 Neutrophils
( 106/ml)
MMP-1 0.42*** 0.43***
MMP-2 0.08 0.12
MMP-3 0.16 0.03
MMP-8 0.51*** 0.30*
MMP-9 0.52*** 0.42***
MMP-9 activity 0.66*** 0.45***
TIMP-1 0.50*** 0.45***
*Data are Spearman’s rank correlation coefficients, *Po0.05, *act the effects of the numerous MMPs that are
elevated in COPD, leading to a protease–antipro-
tease imbalance and an enhanced proteolytic
environment.
In the present study, levels of MMPs or TIMP-1
were not elevated in our asthmatic patients. This is
in contrast to certain other studies.17,18,21,25,32,34,35
The reason(s) for these discrepancies may reflect
asthma severity, with our patients being milder
than in the studies cited above. Consequently, it is
possible that the lungs of our asthmatic patients
exhibited less remodelling than those with more
severe disease. Part of the remodelling process
might be due to the activity of MMPs, which would
be less marked in these milder patients. Consistent
with this suggestion is the observation that MMP-9
levels are greater in BAL fluid and induced sputum
of patients with severe asthma compared with
patients with mild or moderate asthma.34,36 The
increase in MMP-9 may reflect an increase in
neutrophils that are found in the induced sputum
of patients with severe asthma and during exacer-
bations.37,38
In the present study, lung function was inversely
related to MMP-1, -8,-9 and TIMP-1 levels. This is
consistent with a number of other diverse observa-
tions.18,26,36,39 The negative correlation between
MMP-1 and FEV1 in the current study has not been
reported previously, although polymorphisms in the
MMP-1 and -12 genes, but not the MMP-9 gene, are
associated with a rapid decline in lung function in
cigarette smokers.40 This relationship may be due
to increased inflammatory cell infiltrate in these
conditions, and consistent with the positive corre-
lations observed between neutrophils and MMP-9 in
asthmatic or COPD sputum.26,39,41
The differences in MMP expression between
asthmatics and patients with COPD seen herein
may reflect chronicity of disease. Our asthmatic
patients were relatively mild, whereas our COPD
patients were moderate to severe (Table 1).ng function and sputum inflammatory cells*.
Neutrophils
(%)
Macrophages
( 106/ml)
Macrophages
(%)
0.61*** 0.06 0.60***
0.19 0.17 0.15
0.03 0.02 0.06
0.63*** 0.23 0.57***
0.76*** 0.19 0.74***
0.72*** 0.18 0.73***
0.78*** 0.15 0.74***
**Po0.001.
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Figure 3 Relationship between MMP-8 concentrations and MMP-9 activity with lung function and sputum inflammatory
cells. Panels A–C ¼ MMP-8 vs. FEV1, % neutrophils and % macrophages respectively; panels D–F ¼ MMP-9 vs. FEV1, %
neutrophils and % macrophages, respectively. J ¼ controls, K ¼ asthmatics, & ¼ smokers, ’ ¼ COPD patients.
r ¼ Spearman’s rank correlation coefficient.
Sputum MMPs in COPD and asthma 709However, the two groups were matched for
pharmacotherapy (bronchodilator treatment
alone). This is relevant because inhaled glucocorti-
costeroids down-regulate expression of MMP-9 in
asthmatics.27 The lack of differences in any of the
MMPs between the normal controls and the asth-
matic patients possibly reflects the relative mild-
ness of disease in the asthmatic group. The
increased concentrations of MMP-1, -8 and -9 in
the COPD patients compared with the asthmatics
may reflect the destructive nature of COPD.
Although airway remodelling is a feature of asthma,
it is not the tissue destruction characteristic of
emphysema. Therefore, the enhanced levels of
MMP expression, together with MMP-9 activity,
reflect the enhanced pulmonary proteolytic load
in COPD.
In summary, the present study demonstrates
increased concentrations of MMP-1, -8, -9 activity
and TIMP-1 in induced sputum from COPD patients
compared with patients with mild asthma, cigar-
ette smokers or control subjects. Cigarette smokers
have increased levels of MMP-9 and TIMP-1 com-
pared with asthmatics and controls, and greater
MMP-9 activity than controls. MMP-8 concentrations
and MMP-9 activity correlate negatively with FEV1,and are positively correlated with the percentage
and number of neutrophils. In conclusion, the MMP
profile of COPD patients differs to that seen in mild
asthmatics, and may contribute to, or be a marker
of, the different pathophysiologies of asthma and
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